KEAP1 and glioma: KEAP1 point mutations were reported in multiple solid cancers with different incidences, such as gastric (11.1%), liver (2–8%), colorectal (7.8%), prostate (1.3%), gallbladder (30.7%), ovarian (37%), glioma (1.7%), head and neck (42%), clear renal cell carcinoma (4.7%) and large cell lung carcinoma (31%), [2,13,14,15,16,17,18,19,20,21,22].